Clifford Chance Advises on Onward Medical's €50 Million Capital Increase

"Clifford Chance has advised underwriters on Onward Medical NV's €50 million capital increase, the largest European medtech primary capital raise of the year. The funds will support development initiatives and operational expansion for the neurotechnology company, which focuses on therapies for spinal cord injuries and movement disabilities. The capital increase was executed through a private placement with institutional investors, and shares were listed on Euronext exchanges on October 28, 2025."

**Law Firms Involved in the Transaction:** Clifford Chance advised the underwriters, UBS, Stifel, and Bank Degroof Petercam SA/NV, in the capital increase transaction for Onward Medical NV. **Transaction Overview:** Onward Medical NV successfully raised approximately €50 million through a one-day fully marketed bookbuild offering via a private placement with institutional investors. This capital increase marks the largest primary capital raise in the European MedTech sector for the year. The net proceeds will be utilized for various purposes, including funding development initiatives, expanding sales and operations, supporting quality and administrative activities, and covering financing costs. The settlement of the shares and their admission to listing and trading on Euronext Brussels, Euronext Amsterdam, and Euronext Paris occurred on 28 October 2025. **Legal Team:** The Clifford Chance team was led by Olivier Plessis and Han Teerink, with support from Maks Mencin (Frankfurt), Marina Sarkisjan and Robert Bulte (Amsterdam), and Johannes Juette (London). The press release does not specify the seniority or practice areas of the individual lawyers involved.

Clifford Chance Advises on Onward Medical's €50 Million Capital Increase

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads